[go: up one dir, main page]

MX2012003539A - Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac). - Google Patents

Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).

Info

Publication number
MX2012003539A
MX2012003539A MX2012003539A MX2012003539A MX2012003539A MX 2012003539 A MX2012003539 A MX 2012003539A MX 2012003539 A MX2012003539 A MX 2012003539A MX 2012003539 A MX2012003539 A MX 2012003539A MX 2012003539 A MX2012003539 A MX 2012003539A
Authority
MX
Mexico
Prior art keywords
indole derivatives
crac
compounds
crac modulators
modulators
Prior art date
Application number
MX2012003539A
Other languages
English (en)
Inventor
Daisy Joe Du Bois
Ronald Charles Hawley
Wylie Solang Palmer
Robert Stephen Wilhelm
Tania Silva
Joshua Kennedy-Smith
Muzaffar Alam
Ana Elena Minatti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012003539A publication Critical patent/MX2012003539A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Compuestos de la fórmula I: (ver fórmula (I)) o sales farmacéuticamente aceptables de los mismos, en la que R1, R2, R3 y R4 tienen los significados aquí definidos. Se describen también métodos de obtención de los compuestos y el uso de los compuestos para el tratamiento de enfermedades asociadas con los canales de calcio activados con la liberación de calcio (CRAC).
MX2012003539A 2009-09-24 2010-09-21 Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac). MX2012003539A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24552109P 2009-09-24 2009-09-24
US37806210P 2010-08-30 2010-08-30
PCT/EP2010/063838 WO2011036130A1 (en) 2009-09-24 2010-09-21 Indole derivatives as crac modulators

Publications (1)

Publication Number Publication Date
MX2012003539A true MX2012003539A (es) 2012-04-30

Family

ID=43432437

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003539A MX2012003539A (es) 2009-09-24 2010-09-21 Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).

Country Status (12)

Country Link
US (1) US20110071150A1 (es)
EP (1) EP2480529A1 (es)
JP (2) JP2013505913A (es)
KR (1) KR20120068947A (es)
CN (1) CN102574788A (es)
AR (1) AR078408A1 (es)
BR (1) BR112012006630A2 (es)
CA (1) CA2771026A1 (es)
MX (1) MX2012003539A (es)
RU (1) RU2012116207A (es)
TW (1) TW201121952A (es)
WO (1) WO2011036130A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
WO2011158108A2 (en) * 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
US20130109720A1 (en) * 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
WO2013092444A1 (en) * 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag Diazaindole inhibitors of crac
US20130158066A1 (en) * 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 4-azaindole inhibitors of crac
WO2013092467A1 (en) * 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag 7-azaindole inhibitors of crac
EP2909172A1 (en) * 2012-10-17 2015-08-26 F. Hoffmann-La Roche AG 6-aminoindole derivatives as trp channel antagonists
JP5758864B2 (ja) 2012-11-08 2015-08-05 ファナック株式会社 ブレーキの状態を解放状態から締結状態に迅速に変更するブレーキ駆動制御装置
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
EP2970119B1 (en) * 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
AR097325A1 (es) * 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
CN105722834B (zh) 2013-12-13 2017-12-22 豪夫迈·罗氏有限公司 酪氨酸蛋白激酶抑制剂
WO2015086635A1 (en) 2013-12-13 2015-06-18 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
CN104447490B (zh) * 2014-11-19 2017-06-06 连云港恒运医药有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途
MX378998B (es) 2015-06-03 2025-03-11 Bristol Myers Squibb Co Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
TW201835036A (zh) 2017-02-27 2018-10-01 瑞士商隆薩有限公司 製備1-甲基-3-(三氟甲基)-1h-吡唑-5-醇的方法
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP3710440B1 (en) 2017-11-14 2023-04-05 Bristol-Myers Squibb Company Substituted indole compounds
SG11202005513TA (en) 2017-12-15 2020-07-29 Bristol Myers Squibb Co Substituted indole ether compounds
AU2018390820A1 (en) 2017-12-19 2020-08-06 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
AU2018392316B2 (en) 2017-12-19 2022-05-12 Bristol-Myers Squibb Company Amide substituted indole compounds useful as TLR inhibitors
CN111699185B (zh) 2017-12-19 2023-06-27 百时美施贵宝公司 6-氮杂吲哚化合物
KR102714788B1 (ko) 2017-12-20 2024-10-08 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 아미노 인돌 화합물
JP7382938B2 (ja) 2017-12-20 2023-11-17 ブリストル－マイヤーズ スクイブ カンパニー ジアザインドール化合物
JP7291707B2 (ja) * 2017-12-20 2023-06-15 ブリストル－マイヤーズ スクイブ カンパニー アリールおよびヘテロアリール置換されたインドール化合物
EA202190556A1 (ru) 2018-09-14 2021-08-24 Ризен Фармасьютикалс А Г Композиции, содержащие ингибитор crac и кортикостероид, и способы их применения
EP3628669A1 (en) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
WO2020086503A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
JP7597710B2 (ja) 2018-10-24 2024-12-10 ブリストル－マイヤーズ スクイブ カンパニー 置換インドール二量体の化合物
ES2987832T3 (es) 2019-05-09 2024-11-18 Bristol Myers Squibb Co Compuestos de benzimidazolona sustituidos
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
US12384760B2 (en) 2019-10-04 2025-08-12 Bristol-Myers Squibb Company Substituted carbazole compounds
BR112023002737A2 (pt) 2020-08-19 2023-03-14 Bristol Myers Squibb Co Derivados de imidazo[1,2-a]piridina e [1,2,4]triazolo[1,5-a]piridina como inibidores de tlr9 para o tratamento de fibrose
CN115043770B (zh) * 2022-07-21 2023-09-08 南京大学 一种吲哚/氮杂吲哚类化合物的光诱导合成方法
CN115124410B (zh) * 2022-08-13 2024-06-04 上海珂华生物科技有限公司 一种2-氟-4-羟基苯甲醛的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5785055A (en) * 1980-11-18 1982-05-27 Konishiroku Photo Ind Co Ltd Silver halide photographic recording material
JP2894617B2 (ja) * 1989-12-16 1999-05-24 帝国臓器製薬株式会社 ２―フエニルインドール誘導体
FR2824827B1 (fr) * 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
WO2003099206A2 (en) * 2002-05-21 2003-12-04 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
SI1986633T1 (sl) * 2006-02-10 2015-03-31 Summit Corporation Plc Zdravljenje Duchennove mišične distrofije
US20090142832A1 (en) * 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
US8785489B2 (en) * 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
KR20100092909A (ko) * 2009-02-13 2010-08-23 주식회사 엘지생명과학 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
MA33209B1 (fr) * 2009-03-27 2012-04-02 Merck Sharp & Dohme Inhibiteurs de la replication du virus de l'hepatite c

Also Published As

Publication number Publication date
US20110071150A1 (en) 2011-03-24
CA2771026A1 (en) 2011-03-31
WO2011036130A1 (en) 2011-03-31
CN102574788A (zh) 2012-07-11
KR20120068947A (ko) 2012-06-27
JP2012246302A (ja) 2012-12-13
EP2480529A1 (en) 2012-08-01
TW201121952A (en) 2011-07-01
AR078408A1 (es) 2011-11-02
RU2012116207A (ru) 2013-10-27
BR112012006630A2 (pt) 2016-05-03
JP2013505913A (ja) 2013-02-21

Similar Documents

Publication Publication Date Title
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
PH12013500880A1 (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MX2012002387A (es) Aminas de triazol fusionadas como moduladores p2x7.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
SG178952A1 (en) Chemical compounds
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
EA201100992A1 (ru) Карбазолкарбоксамидные соединения, применимые в качестве ингибиторов киназы
PH12012502373A1 (en) Aminopyrimidine derivatives as lrrk2 modulators
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
MX356644B (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
MX2014006210A (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
GEP20146082B (en) Compositions and methods of wnt signaling modulators
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
TN2012000248A1 (en) Novel spiropiperidine compounds
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
IN2012DN03182A (es)
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
TW200738651A (en) Cyclohexyl sulfonamide derivatives
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
UA99787C2 (en) Lactams as beta secretase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal